Canadian Treatments for COVID-19

This national clinical trial plans to identify the optimal treatments for hospitalized patients with COVID19. It is an unprecedented opportunity for collaboration, in unprecedented times.
In conjunction with the World Health Organization, Canada is participating in the SOLIDARITY trial, a global platform of research that is in various stages of approval in over 90 countries. This trial, with a common control arm and shared randomization, will generate rapidly applicable data for patients around the world. New arms will be added as they emerge, and arms that demonstrate harm or futility will be removed through frequent interim analyses by a global DSMB.

In Canada, we are currently randomizing hospitalized patients with confirmed COVID19 to one of:

• Optimized supportive care
• Optimized supportive care + Remdesivir
• Optimized supportive care + Lopinavir/ritonavir
• Optimized supportive care + Hydroxychloroquine

The primary outcome is hospital mortality.

This simple trial is currently enrolling across Canada, and Canada is informing the global clinical trials response. Funding is through CIHR.

For more information, click here to email for a start-up package, including the protocol, case report forms, and start-up slides.